Ceronco Biosciences develops novel therapeutics in oncology by targeting the tumor cell membrane.
Our Short-Chain Lipid (SCL) technology modulates the tumor cell membrane, enhancing the uptake of most chemotherapeutic drugs in tumor cells significantly. This will lead to drugs with higher efficacy and fewer side effects, thus increasing the therapeutic window. In addition, increasing the cellular drug influx has the potential to overcome resistance to current cancer therapies.
It is our goal to deliver new drugs to the market which are more effective and/or have fewer side effects, improving the live of patients with cancer.
On 10th September Lilia Pedrosa obtained her doctorate degree at the Erasmus University, Rotterdam, The Netherlands
Ceronco will be present at the BioPharm America conference, held on 21-24 September 2014 in Boston.
Feel free to contact us to set up a meeting
Recent publication by Albert van Hell from the research group at the Netherlands Cancer Institute (Prof Marcel Verheij) shows the importance of the lipid composition of membranes in relationship to the passage of small molecules, and the facilitating effect on this by short-chain lipids.
van Hell, A.J. et al. Membrane organization determines barrier properties of cells and short-chain sphingolipid-facilitated doxorubicin influx. BBA 2014, 1841: 1301-1307